Cargando…
Establishment and Verification of a Predictive Model for Node Pathological Complete Response After Neoadjuvant Chemotherapy for Initial Node Positive Early Breast Cancer
OBJECTIVE: Axillary node status after neoadjuvant chemotherapy (NCT) in early breast cancer patients influences the axillary surgical staging procedure. This study was conducted for the identification of the likelihood of patients being node pathological complete response (pCR) post NCT. We aimed to...
Autores principales: | Zhu, Jiujun, Jiao, Dechuang, Yan, Min, Chen, Xiuchun, Wang, Chengzheng, Lu, Zhenduo, Li, Lianfang, Sun, Xianfu, Qin, Li, Guo, Xuhui, Zhang, Chongjian, Qiao, Jianghua, Li, Jianbin, Fan, Zhimin, Wang, Haibo, Zhang, Jianguo, Yin, Yongmei, Fu, Peifen, Geng, Cuizhi, Jin, Feng, Jiang, Zefei, Cui, Shude, Liu, Zhenzhen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117332/ https://www.ncbi.nlm.nih.gov/pubmed/33996607 http://dx.doi.org/10.3389/fonc.2021.675070 |
Ejemplares similares
-
Neoadjuvant Efficacy of Three Targeted Therapy Strategies for HER2-Positive Breast Cancer Based on the Same Chemotherapy Regimen
por: Zhu, Jiujun, et al.
Publicado: (2022) -
A Nomogram for Identifying HR+/Her2− Breast Cancer Patients with Positive Sentinel Lymph Nodes and Omitted Axillary Lymph Node Dissection Who Need Abemaciclib Therapy
por: Yang, Hanzhao, et al.
Publicado: (2023) -
Effect of the HER-2/CEP17 ratio in IHC 2+/FISH-amplified breast cancer on pathological complete response to neoadjuvant pertuzumab and trastuzumab treatment—a retrospective cohort study
por: Wang, Jiabin, et al.
Publicado: (2022) -
Association of higher axillary pathologic complete response rate with breast pathologic complete response after neoadjuvant chemotherapy
por: Zhu, Jiujun, et al.
Publicado: (2020) -
Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin in early triple-negative breast cancer: a single-arm phase II trial
por: Wang, Chengzheng, et al.
Publicado: (2023)